Insulin resistance (IR) is defined by the inability of insulin to exert its metabolic actions, due to impaired activation of intracellular insulin signaling. This condition is caused by genetic defects or by environmental conditions, among which the most common is obesity. Systemic IR determines the development of hepatic fat accumulation, which can progress to nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma, and is a major determinant of liver disease independently of coexisting factors. Therefore, insulin-sensitizing drugs are currently under evaluation to improve steatohepatitis. Indeed, manipulation of nuclear hormone receptors is already under scrutiny for liver disease prevention by amelioration of IR, whereas NOTCH signaling inhibition represents a novel approach. Nevertheless, further research is warranted to better understand the mechanism linking IR to progressive fibrogenesis in the absence of inflammation and to identify novel drug targets.

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development : a potential therapeutic target? / L. Valenti, M. Meroni, R. Rametta, P. Dongiovanni. - In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1747-4124. - 10:2(2016 Feb), pp. 229-242. [10.1586/17474124.2016.1110018]

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development : a potential therapeutic target?

L. Valenti
Primo
;
M. Meroni;R. Rametta
Penultimo
;
P. Dongiovanni
Ultimo
2016

Abstract

Insulin resistance (IR) is defined by the inability of insulin to exert its metabolic actions, due to impaired activation of intracellular insulin signaling. This condition is caused by genetic defects or by environmental conditions, among which the most common is obesity. Systemic IR determines the development of hepatic fat accumulation, which can progress to nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma, and is a major determinant of liver disease independently of coexisting factors. Therefore, insulin-sensitizing drugs are currently under evaluation to improve steatohepatitis. Indeed, manipulation of nuclear hormone receptors is already under scrutiny for liver disease prevention by amelioration of IR, whereas NOTCH signaling inhibition represents a novel approach. Nevertheless, further research is warranted to better understand the mechanism linking IR to progressive fibrogenesis in the absence of inflammation and to identify novel drug targets.
insulin resistance; insulin receptor signaling; liver disease progression; metformin; nonalcoholic fatty liver disease; obesity; obethicholic acid; pioglitazone; steatohepatitis; type 2 diabetes
Settore MED/09 - Medicina Interna
feb-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Exp Rev GH.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 380.54 kB
Formato Adobe PDF
380.54 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/429113
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
social impact